SLC6A14: A Potential Drug Target and Biomarker (G11254)

Target Name: SLC6A14

NCBI ID: G11254

SLC6A14

SLC6A14: A Potential Drug Target and Biomarker

Solute Carrier Family 6 (SLC6A) is a family of transmembrane proteins that play a significant role in various physiological processes in the body. One of the SLC6A proteins is SLC6A14, which is a member of this family and has been identified as a potential drug target and biomarker.

SLC6A14 is a 14-kDa protein that is expressed in various tissues and organs, including brain, heart, kidney, and liver. It is localized to the endoplasmic reticulum (ER) and is predominantly expressed in the periblastoma, which is a type of cancer that develops from surrounding cells.

SLC6A14 functions as a carrier protein for various molecules, including small molecules, ions, and solutes. It is involved in the transport of various substances across the membrane of the endoplasmic reticulum, including drugs that have been shown to be effective in treating various diseases, such as cancer, neurodegenerative diseases, and metabolic disorders.

SLC6A14 has also been identified as a potential biomarker for several diseases, including cancer. Its expression has been shown to be elevated in various types of cancer, including breast, ovarian, and colorectal cancer. Additionally, it has been shown to be associated with poor prognosis in patients with these diseases.

SLC6A14 is also a potential drug target for several diseases, including neurodegenerative diseases and psychiatric disorders. Its expression has been shown to be elevated in individuals with Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Additionally, it has been shown to be involved in the regulation of neurotransmitter release and cell signaling, which may be a potential target for these disorders.

SLC6A14 is also involved in the regulation of ion transport and has been shown to be involved in the transport of ions, such as Na+ and K+, across the endoplasmic reticulum. This may be a potential target for diseases that involve ion imbalances, such as hyponatremia.

In addition to its potential drug and biomarker applications, SLC6A14 is also involved in several other physiological processes in the body. It is involved in the regulation of cell adhesion and signaling, as well as in the regulation of cell growth and apoptosis.

Overall, SLC6A14 is a protein that has significant potential as a drug target and biomarker. Its localization to the endoplasmic reticulum and its involvement in various physiological processes make it an attractive target for drug development. Additionally, its potential as a biomarker for several diseases, including cancer, neurodegenerative diseases, and psychiatric disorders, makes it an important molecule to study further. Further research is needed to fully understand the role of SLC6A14 in these diseases and to develop effective treatments.

Protein Name: Solute Carrier Family 6 Member 14

Functions: Amino acid transporter that plays an important role in the absorption of amino acids in the intestinal tract. Mediates the uptake of a broad range of neutral and cationic amino acids (with the exception of proline) in a Na(+)/Cl(-)-dependent manner (PubMed:10446133). Transports non-alpha-amino acids such as beta-alanine with low affinity, and has a higher affinity for dipolar and cationic amino acids such as leucine and lysine (PubMed:18599538). Can also transport carnitine, butirylcarnitine and propionylcarnitine coupled to the transmembrane gradients of Na(+) and Cl(-) (PubMed:17855766)

The "SLC6A14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC6A14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets